BNP Paribas Financial Markets
VERV

BNP Paribas Financial Markets’s Verve Therapeutics VERV Stock Holding History

BNP Paribas Financial Markets’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-566,204
Closed -$6.36M – 5788
2025
Q2 		$6.36M Buy
566,204
+560,571
+9,952% +$3.2M ﹤0.01% 1719
2025
Q1 		$25.7K Sell
5,633
-3,243
-37% -$21.7K ﹤0.01% 4465
2024
Q4 		$50.1K Buy
+8,876
New +$50.1K ﹤0.01% 4433

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BNP Paribas Financial Markets's VERV Position: Q3 2025 in Review

BNP Paribas Financial Markets sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 566,204 shares — an estimated $6.36M sold.

BNP Paribas Financial Markets first reported a position in VERV in Q4 2024 and held it in 3 quarters. The position peaked at $6.36M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • BNP Paribas Financial Markets reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 566,204 Verve Therapeutics shares in Q3 2025, an estimated $6.36M.
  • BNP Paribas Financial Markets first reported a position in Verve Therapeutics in Q4 2024 and held it in 3 quarters.
  • BNP Paribas Financial Markets's Verve Therapeutics position peaked at $6.36M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.